Our innovations and drug development approach are based on precedent. Decades of work on molecular targets, drug SAR (structure-activity relationship), polymer conjugation theory and clinical experience have informed our drug development program.
Using 30+ years of accumulated clinical knowledge, we have developed best-in-class fumagillol-polymer conjugates. They combine highly active, novel fumagillol derivatives conjugated to a stable, bio-compatible polymer.
SynDevRx has developed proprietary drug conjugation chemistries (composition of matter) that increase the activity of small molecule drugs while improving their safety profile and physical attributes.
NB: SynDevRx is not affiliated with Children's Hospital Boston.